Triple-Drug attack on tough leukemia shows promise but trial halted
NCT ID NCT04435691
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a combination of three drugs—magrolimab, azacitidine, and venetoclax—in 110 adults with acute myeloid leukemia that had come back or not responded to treatment. The goal was to find the best dose and see if the combination could put the cancer into remission. However, the study was terminated early, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- magrolimab, azacitidine, and venetoclax
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with hard-to-treat acute myeloid leukemia.
- What could go wrong
- The trial was terminated early, so results are limited. The combination may cause significant side effects, and it is unclear if it works better than existing therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?